AU2022385450A1 - Methods for enhancing adoptive cell transfer immunotherapies - Google Patents

Methods for enhancing adoptive cell transfer immunotherapies Download PDF

Info

Publication number
AU2022385450A1
AU2022385450A1 AU2022385450A AU2022385450A AU2022385450A1 AU 2022385450 A1 AU2022385450 A1 AU 2022385450A1 AU 2022385450 A AU2022385450 A AU 2022385450A AU 2022385450 A AU2022385450 A AU 2022385450A AU 2022385450 A1 AU2022385450 A1 AU 2022385450A1
Authority
AU
Australia
Prior art keywords
igg
cells
protein
car
adoptive cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022385450A
Other languages
English (en)
Inventor
Robert BOCKERMANN
Gianpietro Dotti
Christian Kjellman
Raghuveer RANGANATHAN
Anna-Karin ROBERTSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of AU2022385450A1 publication Critical patent/AU2022385450A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01169—Protein O-GlcNAcase (3.2.1.169)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022385450A 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies Pending AU2022385450A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279398P 2021-11-15 2021-11-15
US63/279,398 2021-11-15
PCT/EP2022/081841 WO2023084095A2 (en) 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies

Publications (1)

Publication Number Publication Date
AU2022385450A1 true AU2022385450A1 (en) 2024-06-13

Family

ID=84463039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022385450A Pending AU2022385450A1 (en) 2021-11-15 2022-11-14 Methods for enhancing adoptive cell transfer immunotherapies

Country Status (7)

Country Link
US (1) US20250325640A1 (https=)
EP (1) EP4433587A2 (https=)
JP (1) JP2024544565A (https=)
CN (1) CN119013396A (https=)
AU (1) AU2022385450A1 (https=)
CA (1) CA3237815A1 (https=)
WO (1) WO2023084095A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025014862A1 (en) * 2023-07-07 2025-01-16 Emory University Recombinant glycosidases, pharmaceutical compositions, and uses in managing autoimmune or inflammatory conditions
WO2025030053A1 (en) * 2023-08-01 2025-02-06 Insmed Incorporated Novel igg proteases and methods of use thereof
CN120334552B (zh) * 2025-06-12 2025-09-12 成都蓉生药业有限责任公司 一种人免疫球蛋白对非人种属细胞的adcp活性的检测试剂的组合、检测试剂盒及其检测方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
CN114450397A (zh) * 2019-08-01 2022-05-06 纪念斯隆-凯特琳癌症中心 用于改善免疫疗法的细胞及其用途
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods

Also Published As

Publication number Publication date
JP2024544565A (ja) 2024-12-03
CN119013396A (zh) 2024-11-22
WO2023084095A3 (en) 2023-07-20
CA3237815A1 (en) 2023-05-19
WO2023084095A2 (en) 2023-05-19
US20250325640A1 (en) 2025-10-23
EP4433587A2 (en) 2024-09-25

Similar Documents

Publication Publication Date Title
US20250325640A1 (en) Methods for enhancing adoptive cell transfer immunotherapies
Caminschi et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement
JP6931329B2 (ja) 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
EP2946791B1 (en) Anti-CD277 antibodies and uses thereof
EP4153194B1 (en) Methods for enhancing adoptive cell transfer immunotherapies
CN110267978A (zh) 用于治疗癌症的表达膜锚定的il-12的t细胞
CN112469479A (zh) 治疗癌症和自身免疫性疾病的试剂和方法
ES2928167T3 (es) Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos
Mason et al. Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
KR20220032642A (ko) 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
US10934331B2 (en) Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells
JP2021513570A (ja) サイトカインをコードするｒｎａを用いた治療
US20150368316A1 (en) A selective high-affinity immune stimulatory reagent and uses thereof
US12325754B2 (en) Cancer and B-cell related disease therapy
Mobergslien et al. Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth
CA3152429A1 (en) Treatment involving therapeutic antibody and interleukin-2 (il2)
US20240350630A1 (en) Compositions and methods of treating disease with chimeric antigen receptors to b cell maturation antigen (bcma)
Puri The Evaluation of MS4A4A and MS4A8B Expression in Hematopoietic Cells
TW202413412A (zh) 在組合療法中能夠結合到ｃｄ２７之結合劑
Solomon Targeting regulatory T cells for therapeutic gain in cancer therapy
Watkins Antibody Targeting of Antigen to Endogenous Immune Surveillance Pathways for the Induction of Tolerance
Hammond Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein Michael D. Oberst, Catherine Augé, Chad Morris, Stacy Kentner, Kathy Mulgrew, Kelly McGlinchey, James Hair, Shino Hanabuchi, Qun Du 2, Melissa Damschroder 2, Hui Feng 2, 10, Steven Eck 3, Nicholas Buss 4, Lolke de Haan 4, Andrew J. Pierce 5, Haesun Park 6, Andrew